Fortis Life Sciences announced the acquisition of IPOC (International Point of Care Incorporated) in early July. Headquartered in Toronto, Canada, IPOC focuses on rapid point-of-care testing, providing Primecare blood separation membranes, antibodies, recombinant proteins and customized lyophilized beaded reagents, etc., to provide global customers with more Complete and diverse solutions.

IPOC has a GMP and ISO 13485 compliant factory covering an area of 36,000 square feet. Its facilities include more than 4,000 square feet of low humidity Class 8 environmental rooms, 500 square feet of development dry room with 4 pilot scale lyophilizers, high humidity environmental control rooms, blood separation membrane production facilities, and a bioreactor production library.

At present, the blood separation membrane produced by IPOC has been used by several international manufacturers. The difference in pore size is designed to capture blood cells, make the blood cells and plasma separated, and the plasma part is used for subsequent detection. In terms of lyophilization, they can produce up to 20 million lyophilized beads per month. In addition, IPOC has more than 60 scientists in the team to bring the best solutions to customers!

In addition to blood separation membranes, Reman also provides nanoComposix nanoparticles and Arista antibodies/antigens to help you develop products in the field of point-of-care diagnostic!

If you have related needs or questions, please feel free to contact us!